Cirrhosis
Conditions
Interventions
Case group (Patients with confirmed cirrhosis, esophageal and gastric varices, and no bleeding or death occurred):None
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients with confirmed cirrhosis: meet clinical diagnostic criteria or confirm cirrhosis by imaging (e.g., ultrasound, CT, or MRI) or liver biopsy. 2.Presence of esophageal or gastric varices: patients with endoscopically confirmed esophageal or gastric varices. 3.Age: Adult patients between the ages of 18-75 years. 4.Follow-up records: at least half a year of follow-up records (including records of bleeding events, death events, or other adverse outcomes, for the validation of risk prediction models. );
Exclusion criteria
Exclusion criteria: 1.Patients with other malignancies: patients with comorbid malignancies (e.g., cancers other than liver cancer) may affect survival and bleeding risk, thus interfering with the predictive accuracy of the model. 2.Combined with other serious chronic diseases, such as severe heart and lung diseases, renal failure, etc., may significantly affect the prognosis of patients and lead to confusion about the risk of death. 3.Incomplete clinical data: Patient key clinical data, laboratory indicators, imaging test results, or follow-up data are missing, resulting in incomplete data analysis and risk assessment. 4.Pregnant or lactating women: physiological and pathological status during pregnancy and lactation may be specific, and such patients are generally excluded for ethical reasons. 5.Patients lost to follow-up: lost to follow-up during follow-up, lacking the necessary data on bleeding or death events to be used for the training and validation of predictive models. 6.Patients with portal hypertension due to other liver diseases: including portal hypertension caused by idiopathic portal hypertension, Budd-Chiari syndrome and other non-cirrhosis causes, to ensure the homogeneity of the study subjects and avoid confounding the analysis results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of bleeding events;Occurrence of death events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessment;Biomarker changes;Therapeutic interventions;Frequency and duration of hospitalization; | — |
Countries
China
Contacts
Public ContactYupingYang
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed